Event: | |
Date: | May 7–11, 2024 |
Format: | Oral Presentation/Abstract: Exosome-mediated intracellular delivery of arginase-1: a potential application for the treatment of Arginase-1 Deficiency |
Event: | Parent Project Muscular Dystrophy (PPMD) Cardiac Workshop III ( |
Date: | May 9–10, 2024 |
Format: | Panel: Industry perspectives on cardiac monitoring in DMD clinical trials |
Event: | |
Date: | May 9–12, 2024 |
Format: | Abstract: Targeted cargo delivery to mouse lower limb by exosomes carrying a muscle targeting moiety with intravenous injection |
Event: | CureDuchenne 2024 |
Date: | May 23–26, 2024 |
Format: | Presentation: CAP-1002: an allogeneic cell therapy demonstrates disease modification in later-stage DMD patients: 24-month safety and efficacy results from the HOPE-2 open label extension |
Event: | |
Date: | May 29–June 1, 2024 |
Format: | Oral Presentation/Abstract: Targeted delivery of ASO using exosomes leads to mouse dystrophin exon skipping |
The posters and/or abstracts will be made available on the publications section of the
About
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended
For more information, please contact:
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
Source:
2024 GlobeNewswire, Inc., source